The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Results of CeLEBrATE: carboplatin, etoposide, bevacizumab + atezolizumab ES-SCLC
Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, talks on the results of the multicenter Phase II CeLEBrATE trial (NCT04730999) investigating carboplatin, etoposide, bevacizumab and atezolizumab in patients with extensive-stage small cell lung cancer (ES-SCLC), which will be released in the second half of 2023. The primary endpoint is 1-year overall-survival (OS). This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
![Impact of [18F]FDG PET/CT-derived metabolic parameters on outcomes in extensive-stage SCLC](https://i.ytimg.com/vi/soBIdqv8jvQ/mqdefault.jpg)
